Literature DB >> 14633682

p300 in prostate cancer proliferation and progression.

Jose D Debes1, Thomas J Sebo, Christine M Lohse, Linda M Murphy, De Anna L Haugen, Donald J Tindall.   

Abstract

Although prostate cancer (PCa) is the most frequently diagnosed cancer in males, little is known about the mechanisms involved in its progression. Recent in vitro studies suggest that coactivators of the androgen receptor play an important role in PCa progression. We have shown previously that p300 is involved in androgen receptor transactivation. In the present work, we studied 95 patients with biopsy-proven PCa who underwent prostatectomy as treatment of their tumors between 1995 and 1998. We found that p300 correlated with in vivo proliferation (P = 0.009) as determined by MIB-I expression. Moreover, high levels of p300 in biopsies predicted larger tumor volumes (P < 0.001), extraprostatic extension (P = 0.003), and seminal vesicle involvement (P = 0.002) at prostatectomy, as well as PCa progression after surgery (P = 0.01). Furthermore, we found that the disruption of p300 transcripts through small interfering RNA inhibited PCa cell proliferation both at the basal level and on interleukin 6 stimulation. We conclude that p300 plays an important role in PCa cell proliferation, as well as PCa progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14633682

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  69 in total

1.  MAPK/ERK signaling pathway-induced hyper-O-GlcNAcylation enhances cancer malignancy.

Authors:  Xinling Zhang; Leina Ma; Jieqiong Qi; Hui Shan; Wengong Yu; Yuchao Gu
Journal:  Mol Cell Biochem       Date:  2015-08-29       Impact factor: 3.396

2.  Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.

Authors:  Zehua Wang; Zemin Wang; Jianhui Guo; Yingchun Li; Jasmin H Bavarva; Chiping Qian; M Christiane Brahimi-Horn; Deyong Tan; Wanguo Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 3.  Dynamic regulation of lysine acetylation: the balance between acetyltransferase and deacetylase activities.

Authors:  Kelly A Hyndman; Mark A Knepper
Journal:  Am J Physiol Renal Physiol       Date:  2017-07-12

4.  Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Authors:  Myles C Hodgson; Long-jiang Shao; Anna Frolov; Rile Li; Leif E Peterson; Gustavo Ayala; Michael M Ittmann; Nancy L Weigel; Irina U Agoulnik
Journal:  Cancer Res       Date:  2011-01-11       Impact factor: 12.701

5.  The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.

Authors:  Vasundhra Kashyap; Shafqat Ahmad; Emeli M Nilsson; Leszek Helczynski; Sinéad Kenna; Jenny Liao Persson; Lorraine J Gudas; Nigel P Mongan
Journal:  Mol Oncol       Date:  2013-01-19       Impact factor: 6.603

Review 6.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

7.  p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape.

Authors:  Sumit Isharwal; Michael C Miller; Cameron Marlow; Danil V Makarov; Alan W Partin; Robert W Veltri
Journal:  Prostate       Date:  2008-07-01       Impact factor: 4.104

8.  Interleukin-4 activates androgen receptor through CBP/p300.

Authors:  Soo Ok Lee; Jae Yeon Chun; Nagalakshmi Nadiminty; Wei Lou; Siting Feng; Allen C Gao
Journal:  Prostate       Date:  2009-02-01       Impact factor: 4.104

9.  Gene clusters, molecular evolution and disease: a speculation.

Authors:  Leah I Elizondo; Paymaan Jafar-Nejad; J Marietta Clewing; Cornelius F Boerkoel
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

10.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.